Edelris Announces Collaboration With Merck Serono in Fragment Based Drug Discovery
Edelris announced that they have signed collaboration with Merck Serono, a division of Merck KGaA, Darmstadt,Germany, aiming at the delivery of innovative and exclusive chemical entities for Fragment-Based Drug Discovery (FBDD).
"We are pleased to be collaborating again with Merck Serono on cutting-edge discovery technologies," said Dr. Jean-Yves Ortholand, CEO of Edelris. "Edelris has acquired a unique expertise in the synthesis of biorelevant innovative fragments maximizing 3D-diversity. Our platform has been developed to explore targeted or diversified spaces aiming at providing fragments with high potential for molecular interactions" added Dr.Didier Roche, VP Strategy and Innovation at Edelris.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.